Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Investigational drug lowers angiotensinogen but shows unclear blood pressure benefits

The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused a significant and sustained drop in angiotensinogen but its

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused a significant and sustained drop in angiotensinogen but its impact on blood pressure was less clear, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

High blood pressure, also known as hypertension, damages blood vessels and contributes to cardiovascular disease, dementia and other health problems, yet about half of U.S. adults have uncontrolled hypertension. Tonlamarsen is one of several therapies being developed to help patients who still have hypertension despite being on multiple blood pressure lowering medications. Administered as a monthly injection, tonlamarsen suppresses angiotensinogen, a precursor involved in the production of angiotensin. The Phase 2 trial enrolled 206 patients at 39 U.S. sites who had baseline systolic blood pressure between 135 mmHg-170 mmHg, with an average of 147 mmHg, despite taking two to five blood pressure lowering medications. The average age of participants was 61 years, about half were Black or African American and 41% were female.

After receiving an initial placebo injection, all participants received one dose of tonlamarsen at the start of the trial (week 0). For the four monthly injections from weeks four to 20, half of the participants were randomized to receive tonlamarsen and half placebo.

At 20 weeks, angiotensinogen levels had dropped by 67.2% from baseline, on average, among those who continued taking tonlamarsen and by 23% among those who switched to placebo—one of the study's two primary endpoints. This was a significant between-group difference of 44.1% in favor of continuous tonlamarsen.

Systolic blood pressure readings taken in the clinic, the study's other primary endpoint, dropped by 6.7 mmHg, on average, across both study groups. This decrease occurred after the first dose of tonlamarsen was administered to all participants and was sustained in both study groups at week 20, with no significant between-group difference at this time point. There were also no significant differences in secondary blood pressure outcomes including change in blood pressure measured at home or the percentage of participants achieving target blood pressure levels.

Because the drug was dosed monthly, we predicted that angiotensinogen would be fully back to its baseline levels by 20 weeks, but we found tonlamarsen's effect was much longer acting than we would have predicted. The continued decrease in blood pressure after a single dose surprised us. We also did not anticipate the finding that the percentage of angiotensinogen reduction didn't necessarily correspond to blood pressure lowering 20 weeks out. This trial raises more questions than it gives answers at this point, but it gives us data that's unique." Luke Laffin, MD, cardiologist at Cleveland Clinic and study's lead author

Researchers attribute the mixed results to an unexpectedly long-lasting impact of the drug, which was administered to all study participants at the start of the trial. Four weeks after receiving an initial dose of tonlamarsen, half of the participants switched to a placebo for the remaining 16 weeks, while half continued to receive tonlamarsen. However, the specific drivers behind the mixed findings are not known, although researchers identified several possible explanations.

"One possibility, which we think is most likely, is that tonlamarsen lowers blood pressure by about 6-7 mmHg, and this is maintained even as angiotensinogen levels rise," Laffin said. "Another possibility is that residual angiotensin suppression among placebo participants resulted in greater blood pressure reduction than expected. It's also possible that decreasing angiotensin with tonlamarsen doesn't reduce blood pressure, although we think that's probably not likely based on the fact that blood pressure dropped during the drug run-in period."

Participants randomized to continue tonlamarsen experienced a higher rate of injection-site reactions, which was expected since these participants were receiving drug injections rather than a placebo.

In addition to the unanticipated prolonged suppression of angiotensinogen, Laffin said that the study was relatively small and did not assess cardiovascular outcomes. Researchers are planning a separate study to assess the use of a short course of tonlamarsen in patients with acute severe hypertension.

The study was funded by Kardigan, maker of tonlamarsen.

This study was simultaneously published online in JACC at the time of presentation.

Laffin will present the study, "Kardinal: A Phase 2 Study of Tonlamarsen for the Treatment of Uncontrolled Hypertension," on Saturday, March 28, at 3:45 p.m. CT / 20:45 UTC in the Main Tent, Great Hall.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Your early research focused on predicting molecular properties such as solubility using machine learning. What did that teach you about data-driven property prediction?

Data-driven models, such as Quantitative Structure Activity Relationships (QSAR), are incredibly attractive because they offer rapid methods for predicting molecular properties, including those that are difficult to access through fundamental chemical and physical theory. For new molecules, in related regions of chemical space to the training data, they can often be very accurate. The challenge is that they typically do not generalize across large diverse chemical and biological spaces. Therefore real care is needed when applying them to novel chemistry or biology. Some attempts to build more widely applicable QSAR models have been made in recent years, but most models in use today are still built for specific chemistries and properties owing to the scale and complexity of chemical space. When I started this work, especially for solubility predictions, the datasets were modest by today’s standards, often hundreds to a few thousand molecules. One of the first things that teaches you is to explore the data carefully, assess its quality and quantity, and only then move forward with modeling. The aim is to capture genuine relationships between numerical molecular descriptions and important target endpoints, but those relationships may be only locally generalizable. I also think the phrase “simple descriptors” is interesting. Some are simple, such as atom counts or bond counts, but others rely on detailed parameterization, group contributions, and graph-theoretical techniques. We still see these descriptors used today, sometimes alongside embeddings from graph neural networks or language models. The main lesson for me is that there is no single workflow. Each dataset, model, and end-use case needs careful thought.

Source: www.news-medical.net ↗
02How does this new drug work?

The medication, called daraxonrasib, is the first drug that targets cancer-causing mutations in pancreas cells. The drug targets a mutation in the KRAS gene, part of the RAS genetic family. KRAS mutations are present in 92% of pancreatic cancers. KRAS genes normally act as an "on-off" switch for cell growth. Mutated KRAS genes are stuck in the "on" position and send out a signal that causes cells to divide and grow uncontrollably, allowing cancer to form. Daraxonrasib blocks the KRAS signal by fitting into a keyhole-type spot on the gene. That spot has a complex shape and is difficult to reach within the cell. The drug gets around this problem by using a "passenger protein" as a Trojan horse. When the cell allows this protein in, daraxonrasib tags along.

Source: www.news-medical.net ↗
03What are carbs?

Your weight loss plan should keep you healthy and strong as you lose the extra weight. Many plans include a diet low in carbohydrates. Carb cycling is a method of optimizing your carbohydrate intake to meet your needs while dieting, fasting, and working out. When you're carb cycling, you consume carbs to meet your needs on some days and avoid them on other days. The aim of carb cycling is to consume carbohydrates when your body needs them and exclude them at other times. Such strategies in your diet plan can help your weight loss efforts. Carbohydrates, or carbs, are a significant part of the average human diet. Along with proteins and fats, they make up the bulk of your daily meals. Most carbohydrates are broken down by your body into glucose to provide energy for your cells and tissues. Carbohydrates in your diet are of three types — sugars, starches, and fiber. Sugars are simple carbs. Glucose, sugar (sucrose), lactose found in milk, and fructose found in fruits, are naturally occurring sugars. Your body metabolizes these molecules rapidly to yield energy. Starches are complex carbs. They're large molecules that consist of hundreds of molecules of simple sugars joined together. Your body needs to break them down to release energy. Starches are found in bread, potatoes, peas, corn, cereals, and pasta. Fiber is also a complex carbohydrate. Human bodies can't break down these large molecules, so they provide no energy. They're usually excreted as they are in the feces. They add bulk to your meal, so you feel full. Fiber in the diet helps avoid constipation and lowers blood sugar and cholesterol levels. Carbohydrates are an essential part of your diet. A typical diet provides 45% to 65% of its calories from carbohydrates. If you have 2,000 calories a day, you should have about 275 grams of carbohydrates. Always try to choose healthy foods for your carb intake:

Source: www.medicinenet.com ↗
04Can you please give an overview of BenevolentBio?

What we're trying to do here at Benevolent is develop systems and processes that allow us to tap into the huge amount of public information and some propriety databases that we have paid to access and through that, generate hypotheses which our scientists can then triage. We've got over ten times the amount of information in our database at present (and it’s growing) than we believe that companies such as Watson have. Bringing that and filtering the signals from the ‘noise’ to our experienced drug discovery chemists and biologists, means, firstly, we can reduce the amount of time we take to triage new hypotheses, and secondly, we can develop more predictive chemical tools to allow us to make better molecules and also to reposition existing molecules for new indication.

Source: www.news-medical.net ↗
05From Spirulina to Seaweed: How are different types of algae integral to human diets?

Algae are photosynthetic aquatic creatures that grow through the consumption of nutrients, light, and carbon dioxide. They are a diverse group of creatures that include tiny single-celled algae and enormous kelp, as well as seaweed 1. Numerous prokaryotic and eukaryotic algae species are desirable food sources for humans due to their inherent qualities 2,3. Human intake of macroalgae such as seaweed and microalgae like phytoplankton dates back many years. Multicellular macroscopic aquatic plants, or macroalgae, are classified into three taxa: Phaeophyceae, or brown algae, Rhodophyta or red algae, and Chlorophyta or green algae. Microalgae, the unicellular counterpart of macroalgae, are categorized in a broader framework that includes prokaryotic cyanobacteria (blue-green algae), Euglenophyta, and Chlorophyta, which are genetically distinct from one another. The ancient populations of Chad and the Aztec culture were already familiar with the cyanobacteria spirulina, which is currently advertised as a superfood in the West 4. In Burma, Vietnam, and India, other cyanobacteria/microalgae, like Spirogyra and Oedogonium, were eaten as food or as a supplement 4. Seaweed is a staple of daily meals in many Asian and Pacific civilizations, including Korea, Japan, and Indonesia, as well as Hawaii and New Zealand 5.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →